Human Psychopharmacology: Clinical and Experimental This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A market on both “sides” of the law: The use of the hidden web for the sale of new psychoactive substances
ConclusionsVendors selling and availability of NPS increased over the 12 months of data collection. Potential displacement from the visible Web to hidden Web should be taken into consideration. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 1, 2017 Category: Psychiatry Authors: Elle Wadsworth, Colin Drummond, Andreas Kimerg ård, Paolo Deluca Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

The challenge of complex drug use: Associated use of codeine ‐containing medicines and new psychoactive substances in a European cross‐sectional online population
ConclusionsAmongst NPS users, codeine is less likely to be used daily but more likely to be used for recreational purposes. Smaller populations engaging in high‐risk use exist who take multiple drugs in high doses. Combinations of misused codeine and NPS highlight the need for policy to respond to a more complex drug situation. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 1, 2017 Category: Psychiatry Authors: Andreas Kimerg ård, Michelle Foley, Zoe Davey, Elle Wadsworth, Colin Drummond, Paolo Deluca Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

Altered serum levels of TNF ‐α, IL‐6, and IL‐18 in depressive disorder patients
ConclusionThese findings provided additional evidence that altered TNF‐α, IL‐6, and IL‐18 activities may contribute to the pathophysiology of depressive disorder. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 1, 2017 Category: Psychiatry Authors: Ni Fan, Yayan Luo, Yufen Ou, Hongbo He Tags: RESEARCH ARTICLE Source Type: research

Retraction: ‘Effect of blonanserin on cognitive function in antipsychotic‐naïve first‐episode schizophrenia’
The above article from Human Psychopharmacology, first published on 25 January 2012 in Wiley OnlineLibrary (onlinelibrary.wiley.com), and in Volume 90, pp. 90‐100, has been retracted by agreement between the authors, the journal Editor in Chief, David Baldwin, and John Wiley & Sons Ltd. The retraction has been agreed following an investigation by the St Marianna University Ethics Committee which determined that the paper was not as originally designed and approved. REFERENCESTenjin, T., Miyamoto, S., Miyake, N., Ogino, S., Kitajima, R., Ojima, K., … Yamaguchi, N. (2012). Effect of blonanserin on cognitive function ...
Source: Human Psychopharmacology: Clinical and Experimental - March 1, 2017 Category: Psychiatry Tags: RETRACTION Source Type: research

Interventions for treatment and/or prevention of alcohol hangover: Systematic review
ConclusionThe available evidence suggests that several products are capable of significantly improving some, but not all, of the symptoms related to alcohol hangover. Therefore, further research is necessary to develop clinically effective hangover treatments. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 1, 2017 Category: Psychiatry Authors: Ranil Jayawardena, Thulasika Thejani, Priyanga Ranasinghe, Dinithi Fernando, Joris C. Verster Tags: REVIEW ARTICLE Source Type: research

Recreational stimulants, herbal, and spice cannabis: The core psychobiological processes that underlie their damaging effects
ConclusionsRecreational stimulants such as cocaine or MDMA (3.4‐methylenedioxymethamphetamine) and sedative drugs such as cannabis damage human homeostasis and well‐being through similar core psychobiological mechanisms. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 1, 2017 Category: Psychiatry Authors: Andrew C. Parrott, Amie C. Hayley, Luke A. Downey Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia
ConclusionsLegal sanctions appear to have preceded serious scientific investigations into the claimed benefits of ketum. More objective‐controlled trials and experiments on humans need to be conducted to validate self‐report claims by kratom users in the community. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 1, 2017 Category: Psychiatry Authors: Darshan Singh, Suresh Narayanan, Balasingam Vicknasingam, Ornella Corazza, Rita Santacroce, Andres Roman ‐Urrestarazu Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

New psychoactive substances: Purchasing and supply patterns in Australia
ConclusionNBOMe consumers and those who nominated online markets as their main NPS source reported greater engagement with for‐profit supply; it is unclear if these individuals have “drifted” into dealing or if they were already engaged in such activities. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 1, 2017 Category: Psychiatry Authors: Rachel Sutherland, Raimondo Bruno, Amy Peacock, Paul Dietze, Courtney Breen, Lucinda Burns, Monica J. Barratt Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

An international survey on the awareness, use, preference, and health perception of novel psychoactive substances (NPS)
ConclusionsThese survey data indicate that awareness of NPS and, importantly, perception of the potential health risks associated with NPS use is lacking. NPS awareness and use is higher in those in employment but is unaffected by level of education. This highlights the need for targeted drugs education intervention by policy‐makers in schools and universities. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 1, 2017 Category: Psychiatry Authors: Elena Deligianni, John M. Corkery, Fabrizio Schifano, Lisa A. Lione Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double ‐blind, placebo‐controlled study
ConclusionAn 8‐week course of treatment with cilostazol as an adjunct to risperidone showed a favorable safety and efficacy profile in patients with schizophrenia. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 1, 2017 Category: Psychiatry Authors: Farzin Rezaei, Bita Mesgarpour, Alireza Jeddian, Atefeh Zeionoddini, Payam Mohammadinejad, Elaheh Salardini, Mona Shahriari, Arefeh Zeinoddini, Shahin Akhondzadeh Tags: RESEARCH ARTICLE Source Type: research

The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Barrett & Griffiths (2016)
(Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - January 24, 2017 Category: Psychiatry Authors: Jos é Carlos Bouso, Eduardo José Pedrero‐Pérez, Sam Gandy, Miguel Ángel Alcázar‐Córcoles Tags: LETTER TO THE EDITOR Source Type: research

The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Bouso et al., 2016
(Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - January 24, 2017 Category: Psychiatry Authors: Frederick S. Barrett, Roland R. Griffiths Tags: LETTER TO THE EDITOR Source Type: research

Adjunctive antidepressant use in schizophrenia in China: A national survey (2002 –2012)
ConclusionsDespite an increasing trend, the frequency of antidepressant use in schizophrenia in China was considerably lower than in Western countries. The benefits and risks associated with concomitant use of antidepressants in schizophrenia need to be studied further. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - January 24, 2017 Category: Psychiatry Authors: Qian Li, Yun ‐Ai Su, Yu‐Tao Xiang, Liang Shu, Xin Yu, Gabor S. Ungvari, Chee H. Ng, Helen F.K. Chiu, Yu‐Ping Ning, Gao‐Hua Wang, Ke‐Rang Zhang, Tao Li, Li‐Zhong Sun, Jian‐Guo Shi, Xian‐Sheng Chen, Qi‐Yi Mei, Ke‐Qing Li, Tian‐Mei Si Tags: RESEARCH ARTICLE Source Type: research

A phase I, randomized, proof ‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers
ConclusionsBI 409306 increased rapidly in plasma and was subsequently detected in CSF, resulting in dose‐dependent increases in cGMP levels in CSF. Results indicate BI 409306 efficiently crosses the blood‐CSF barrier, with an acceptable level of AEs. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - January 24, 2017 Category: Psychiatry Authors: Katja Boland, Viktoria Moschetti, Chantaratsamon Dansirikul, Solen Pichereau, Lien Gheyle, Frank Runge, Heike Zimdahl ‐Gelling, Michael Sand Tags: RESEARCH ARTICLE Source Type: research

Association study between the neurexin ‐1 gene and tardive dyskinesia
ConclusionsMore research is needed with additional SNPs and in bigger samples before we can completely rule out the role of NRXN1 in TD. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - January 24, 2017 Category: Psychiatry Authors: Rachel Lanning, Tristram A. Lett, Arun K. Tiwari, Eva J. Brandl, Vincenzo Luca, Aristotle N. Voineskos, Steven G. Potkin, Jeffrey A. Lieberman, Herbert Y. Meltzer, Daniel J. M üller, Gary Remington, James L. Kennedy, Clement C. Zai Tags: RESEARCH ARTICLE Source Type: research